Brief Report: Interleukin‐6 as an Inflammatory Mediator and Target of Therapy in Chronic Periaortitis
Open Access
- 5 June 2013
- journal article
- vasculitis
- Published by Wiley in Arthritis & Rheumatism
- Vol. 65 (9) , 2469-2475
Abstract
Objective: Chronic periaortitis (CP) usually responds to glucocorticoids, but some patients have glucocorticoid‐refractory disease or contraindications to glucocorticoid therapy. This study was undertaken to evaluate treatment with the anti–interleukin‐6 receptor (anti–IL‐6R) antibody tocilizumab in 2 patients with CP, one with refractory disease and the other with contraindications to glucocorticoids, and to assess IL‐6 levels in an additional cohort of patients with CP.Methods: Both patients were given intravenous tocilizumab (8 mg/kg) once every 4 weeks for 6 months. Serum IL‐6 was measured in 22 patients with active CP and 16 healthy controls. Tissue IL‐6 expression was assessed by confocal microscopy in biopsy specimens obtained from 6 patients with CP.Results: In the first patient, whose disease was refractory to various immunosuppressive treatments, tocilizumab added to ongoing therapy with prednisone and methotrexate allowed prednisone withdrawal and induced resolution of symptoms, acute‐phase reactant normalization, and reduction in 18F‐fluorodeoxyglucose (18F‐FDG) uptake on positron emission tomography. The patient experienced a relapse 7 months later and was successfully retreated with tocilizumab. In the second patient, who was unable to tolerate glucocorticoids because of psychiatric side effects, tocilizumab monotherapy induced sustained clinical and laboratory remission, 18F‐FDG uptake disappearance, and CP shrinkage. Serum IL‐6 levels were significantly higher in patients with active CP than in controls (P < 0.0001), and IL‐6 was abundantly expressed in biopsy specimens from CP patients, particularly by T cells, B cells, histiocytes, fibroblasts, and vascular smooth muscle cells.Conclusion: Tocilizumab may be a therapeutic option for CP. The systemic and tissue up‐regulation of IL‐6 in CP, together with the clinical benefit of IL‐6R blockade observed in our 2 patients, suggest that IL‐6 may contribute to CP pathogenesis.Keywords
This publication has 14 references indexed in Scilit:
- Rituximab therapy for chronic periaortitisAnnals of the Rheumatic Diseases, 2012
- Tocilizumab – A novel therapy for non-organ-specific autoimmune diseasesBest Practice & Research Clinical Rheumatology, 2012
- Cyclophosphamide is a highly effective and safe induction therapy in chronic periaortitis: a long-term follow-up of 35 patients with chronic periaortitisAnnals of the Rheumatic Diseases, 2012
- Prednisone versus tamoxifen in patients with idiopathic retroperitoneal fibrosis: an open-label randomised controlled trialThe Lancet, 2011
- Combined Prednisone and Mycophenolate Mofetil Treatment for Retroperitoneal FibrosisAnnals of Internal Medicine, 2011
- Retroperitoneal FibrosisMedicine, 2009
- Chronic periaortitis: a fibro-inflammatory disorderBest Practice & Research Clinical Rheumatology, 2009
- Chronic PeriaortitisCirculation, 2008
- Positron emission tomography (PET): Evaluation of chronic periaortitisArthritis Care & Research, 2005
- The spectrum of chronic periaortitisHistopathology, 1990